Hormonal
Tirzepatide (a dual GIP/GLP-1 receptor agonist) produces significantly greater weight loss and glycemic control than semaglutide (a GLP-1 receptor agonist) in patients with type 2 diabetes and obesity.
If you have type 2 diabetes or obesity, tirzepatide (Mounjaro/Zepbound) is clinically shown to be more effective for weight loss and blood sugar control than semaglutide (Ozempic/Wegovy). It works by targeting two hormones (GLP-1 and GIP) rather than just one. Expect weekly injections and potential stomach upset initially, which usually improves as your dose increases. Consult your doctor to see if this stronger option is appropriate for your specific health profile.
In SURPASS 2, tirzepatide outperformed semaglutide in both HbA1c reduction (1.7% vs. 1.5%) and weight loss (11-12 kg vs. 6-7 kg with semaglutide)... These findings serve to highlight tirzepatide's superior efficacy in promoting weight loss, particularly in patients with obesity.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS-1, SURPASS-2, SURMOUNT-1) cited in the review.
Source
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
Laura Opalska et al. · Quality in Sport · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →